Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
10.04.2024 - Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case studies on NX-5948 demonstrating clinical responses ...
Source: wallstreet-online.de